Dr Amoth emphasised that the medicine is strictly for HIV-negative individuals at risk of infection. “We continue to urge all those on treatment to remain on their lifelong therapy.”Lenacapavir is a long-acting injectable HIV prevention option known as pre-exposure prophylaxis. In addition, he noted, the United States government has committed to support Kenya with a further 25,000 doses, which will strengthen the national rollout and increase access for more Kenyans. The medicine had earlier been approved by the United States Food and Drug Administration in June 2025 and endorsed by the World Health Organisation a month later. “Lenacapavir is going to be a very instrumental piece in providing HIV prevention in the country,” he said.

Source: Standard Digital February 18, 2026 07:54 UTC